protein

ABL1

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about ABL1: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

181Connections

1Hypotheses

0Analyses

50Outgoing

50Incoming

0Experiments

0Debates

Summary

ABL1 non-receptor tyrosine kinase - key regulator of cytoskeleton, DNA damage response, and synaptic function with implications in neurodegenerative diseases

View on Wiki →

No AI portrait yet

🔬 Protein Info

Gene Symbol	ABL1
Aliases	ABL1 non-receptor tyrosine kinase
Chromosome	9q34.
Function	regulator of cytoskeleton
Molecular Weight	120 kDa
Pathways	Pi3K, Akt, Mtor, Oxidative Stress, Necroptosis
GeneCards	ABL1
Human Protein Atlas	ABL1
Associated Diseases	neurodegeneration, Ph-Like ALL
Known Drugs/Compounds	dasatinib, rapamycin
Interactions	ABL2, App, BCL-2, CRLF2, CSF1R, Cytokine
SciDEX Hypotheses	c-Abl Tyrosine Kinase Activation Drives α-Synuclei
KG Connections	181 knowledge graph edges
Databases	GeneCards UniProt NCBI Gene HPA STRING

Wiki Pages (1)

Knowledge base pages for this entity

ABL1 Protein (ABL1 Tyrosine Kinase)

protein · 1550 words

→

Pathway Diagram

graph TD
    ABL1["ABL1"]
    ABL1 -->|"expressed in"| Leukemia["Leukemia"]
    ABL1 -->|"activates"| Als["Als"]
    ABL1 -->|"target for"| Senescence["Senescence"]
    ABL1 -->|"target for"| Ms["Ms"]
    ABL1 -->|"regulates"| Cancer["Cancer"]
    ABL1 -->|"target for"| Inflammation["Inflammation"]
    dasatinib["dasatinib"] -->|"inhibits"| ABL1
    ABL2["ABL2"] -->|"activates"| ABL1
    NTRK3["NTRK3"] -->|"contributes to"| ABL1
    PTK2B["PTK2B"] -->|"contributes to"| ABL1
    ETV6["ETV6"] -->|"expressed in"| ABL1
    PI3K["PI3K"] -->|"regulates"| ABL1
    AKT["AKT"] -->|"regulates"| ABL1
    CANCER["CANCER"] -->|"regulates"| ABL1
    MYC["MYC"] -->|"regulates"| ABL1
    OXIDATIVE_STRESS["OXIDATIVE STRESS"] -->|"target for"| ABL1

Outgoing (126)

Target	Relation	Type	Str
R-HSA-8940973	member_of	pathway	1.00
R-HSA-9664422	member_of	pathway	1.00
R-HSA-2029482	member_of	pathway	1.00
R-HSA-428890	member_of	pathway	1.00
R-HSA-525793	member_of	pathway	1.00
R-HSA-5663213	member_of	pathway	1.00
R-HSA-5685938	member_of	pathway	1.00
R-HSA-5693565	member_of	pathway	1.00
R-HSA-69231	member_of	pathway	1.00
R-HSA-8939236	member_of	pathway	1.00
Ph-Like ALL	causes	disease	0.90
Leukemia	therapeutic_target	disease	0.75
Ms	therapeutic_target	disease	0.65
Senescence	therapeutic_target	disease	0.65
Als	activates	disease	0.65
Leukemia	expressed_in	disease	0.65
Senescence	inhibits	disease	0.65
Cancer	regulates	disease	0.65
Ms	regulates	disease	0.65
ALS	activates	disease	0.65
Tumor	therapeutic_target	disease	0.65
Cancer	therapeutic_target	disease	0.65
Als	therapeutic_target	disease	0.65
Leukemia	inhibits	disease	0.65
Leukemia	activates	disease	0.65
Senescence	activates	disease	0.65
Inflammation	therapeutic_target	disease	0.65
Senescence	regulates	disease	0.65
Anxiety	therapeutic_target	disease	0.65
Als	regulates	disease	0.65
Depression	therapeutic_target	disease	0.65
STAT5	activates	protein	0.64
CSF1R	activates	gene	0.60
EPOR	contributes_to	gene	0.60
TYK2	contributes_to	gene	0.60
IL7R	contributes_to	gene	0.60
PDGFRB	therapeutic_target	gene	0.60
BCL-2	therapeutic_target	gene	0.60
MYC	therapeutic_target	gene	0.60
SRC	therapeutic_target	gene	0.60
PDGFRB	activates	gene	0.60
GENES	expressed_in	gene	0.60
JAK2	activates	gene	0.60
BCL-2	activates	gene	0.60
MYC	activates	gene	0.60
SRC	activates	gene	0.60
FLT3	contributes_to	gene	0.60
Oxidative Stress	therapeutic_target	pathway	0.60
RIPK1	regulates	gene	0.60
MLKL	regulates	gene	0.60

Incoming (55)

Source	Relation	Type	Str
PRKCD	associated_with	gene	0.80
dasatinib	inhibits	drug	0.72
STEM CELLS	targets	cell_type	0.65
LEUKEMIA	targets	disease	0.65
LEUKEMIA	treats	disease	0.65
dasatinib	targets	drug	0.60
GENES	associated_with	gene	0.60
GSK3B	associated_with	gene	0.60
CRLF2	inhibits	gene	0.60
JAK	inhibits	gene	0.60
INFLAMMATION	therapeutic_target	gene	0.60
SIRT1	regulates	gene	0.60
OXIDATIVE STRESS	therapeutic_target	gene	0.60
FLT3	contributes_to	gene	0.60
CRLF2	contributes_to	gene	0.60
TYK2	contributes_to	gene	0.60
EPOR	contributes_to	gene	0.60
IL7R	contributes_to	gene	0.60
GENES	expressed_in	gene	0.60
CSF1R	activates	gene	0.60
PDGFRB	activates	gene	0.60
JAK2	activates	gene	0.60
TSLP	contributes_to	gene	0.60
MYC	inhibits	gene	0.60
BCL-2	inhibits	gene	0.60
SRC	inhibits	gene	0.60
PDGFRB	inhibits	gene	0.60
PTEN	therapeutic_target	gene	0.60
rapamycin	targets	drug	0.60
ABL2	activates	gene	0.60
NTRK3	contributes_to	gene	0.60
PTK2B	contributes_to	gene	0.60
ETV6	expressed_in	gene	0.60
PIK3CA	associated_with	gene	0.60
PARP1	associated_with	gene	0.60
MTOR	associated_with	gene	0.60
CHEK1	associated_with	gene	0.60
AKT	regulates	gene	0.60
CANCER	regulates	gene	0.60
CDK4	associated_with	gene	0.60
CASP3	associated_with	gene	0.60
PI3K	regulates	gene	0.60
MYC	regulates	gene	0.60
IL7R	activates	gene	0.50
NTRK3	activates	gene	0.50
PTK2B	activates	gene	0.50
PDGFRB	expressed_in	gene	0.50
CSF1R	expressed_in	gene	0.50
JAK2	expressed_in	gene	0.50
NTRK3	expressed_in	gene	0.50

Targeting Hypotheses (1)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
c-Abl Tyrosine Kinase Activation Drives α-Synuclein Phosphor	0.605	neurodegeneration	Legacy Pre-Pipeline Hypothesis Import

Mentioning Analyses (0)

Scientific analyses that reference this entity

No analyses mention this entity

Experiments (0)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
No experiments found

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
No papers found

Debates (0)

Multi-agent debates referencing this entity

No debates reference this entity

Related Research

Hypotheses and analyses mentioning ABL1 in their description or question text

No additional research found